Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02980692 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of SUNPG1623
A Phase 2 study of Active Psoriatic Arthritis, sponsored by Sun Pharmaceutical Industries Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 391
- Enrollment target
- 1
- Study location
NCT02980692: Completed Phase 2 study of Active Psoriatic Arthritis, sponsored by Sun Pharmaceutical Industries Limited.
NCT02980692 is a Phase 2 study of Active Psoriatic Arthritis that has completed, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 391 participants, above the 291-participant average among 3 other Active Psoriatic Arthritis trials with a reported enrollment target (34% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02980692, a Phase 2 study of Active Psoriatic Arthritis, has completed, sponsored by Sun Pharmaceutical Industries Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 391 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of SUNPG1623
Primary Outcome
The American College of Rheumatology20 response measured the percentage of subjects with at least a 20% improvement from Baseline in both tender joints (68) and swollen joints (66) and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, patient pain assessment, patient self-assessed disability, and acute-phase C-reactive protein. For 'Units of Measure'- Data entered is proportion of participants, which is calculated by dividing the
Conditions Studied
Interventions
- DRUG PLACEBO
- DRUG SUNPG1623 I
- DRUG SUNPG1623 II
- DRUG SUNPG1623 III
- DRUG SUNPG1623 IV
Study Locations (1)
Ohio
- SPARC Site 1 - Middleburg Heights
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 391 participants |
| Start Date | 2017-04-19 |
| Est. Completion | 2019-09-24 |
| Phase | Phase 2 |
What the finished NCT02980692 record still lists
NCT02980692 is an interventional study that assigns participants to a tested intervention. The registered 391 participants enrollment target is mid-sized for trials with a published cap, above the 291-participant average among 3 other Active Psoriatic Arthritis trials with a reported enrollment target (34% higher).
The record links to 1 condition, with Active Psoriatic Arthritis appearing as the primary indexed condition, and to 5 interventions - of which PLACEBO is the first listed.
NCT02980692 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT02980692 about?
NCT02980692 is a clinical study titled "Efficacy and Safety Study of SUNPG1623". This is a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of SUNPG1623
What is the current status of trial NCT02980692?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 391 participants. The study started on 2017-04-19. Estimated completion is 2019-09-24.
What conditions does trial NCT02980692 study?
This clinical trial studies the following conditions: Active Psoriatic Arthritis.
What interventions are being tested in trial NCT02980692?
The interventions under investigation include: PLACEBO (DRUG), SUNPG1623 I (DRUG), SUNPG1623 II (DRUG), SUNPG1623 III (DRUG), SUNPG1623 IV (DRUG).
Who is sponsoring clinical trial NCT02980692?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02980692 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Active Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)
ACTIVE NOT RECRUITING · Phase 3
-
Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease
COMPLETED · Phase 3
-
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06397703 · 392 participants · Phase 2
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
- NCT06625775 · 392 participants · Phase 1
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- NCT07220967 · 392 participants · Phase 4
A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement
- NCT07290036 · 392 participants · Phase 1
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI